Edward Boyden

Edward S. Boyden is an American neuroscientist at MIT. He is the Y. Eva Tan Professor in Neurotechnology, a faculty member in the MIT Media Lab and an associate member of the McGovern Institute for Brain Research. In 2018 he was named a Howard Hughes Medical Institute Investigator. He is recognized for his work on optogenetics. In this technology, a light-sensitive ion channel such as channelrhodopsin-2 is genetically expressed in neurons, allowing neuronal activity to be controlled by light. There were early efforts to achieve targeted optical control dating back to 2002 that did not involve a directly light-activated ion channel, but it was the method based on directly light-activated channels from microbes, such as channelrhodopsin, emerging in 2005 that turned out to be broadly useful. Optogenetics in this way has been widely adopted by neuroscientists as a research tool, and it is also thought to have potential therapeutic applications. Boyden joined the MIT faculty in 2007, and continues to develop new optogenetic tools as well as other technologies for the manipulation of brain activity. Previously, Boyden received degrees in electrical engineering, computer science, and physics from MIT. During high school, Boyden attended the Texas Academy of Mathematics and Science.

Dr. Boyden is the co-founder of Elemind, a stealth neurotechnology company that augments sleep, attention, and the human experience, as well as Cognito Therapeutics, a company developing therapeutics designed to improve the lives of patients living with neurodegenerative disease.